CN Patent

CN103458881B — Alk抑制剂的使用方法

Assigned to Novartis International Pharmaceutical Ltd · Expires 2015-08-12 · 11y expired

What this patent protects

本发明提供了使用式(I)化合物的方法，这些化合物用于治疗EML4-ALK + 介导的疾病，例如EML4-ALK + 非小细胞肺癌，并任选对克里唑替尼有耐药性的。在式(I)中，R 1 、R 2 、R 3 、R 4 、R 5 和R 6 如说明书所定义。

USPTO Abstract

本发明提供了使用式(I)化合物的方法，这些化合物用于治疗EML4-ALK + 介导的疾病，例如EML4-ALK + 非小细胞肺癌，并任选对克里唑替尼有耐药性的。在式(I)中，R 1 、R 2 、R 3 、R 4 、R 5 和R 6 如说明书所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN103458881B
Jurisdiction
CN
Classification
—
Expires
2015-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Novartis International Pharmaceutical Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.